April 2018 – Page 2 – 1stOncology™: Cancer Intelligence Service

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

SignalRx Announces Discovery of Potent and Selective First-In-Class BRD4-BD1 Inhibitor, SRX3254

On April 30, 2018 SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics to inhibit key orthogonal and synergistic oncotargets for the treatment of cancer, reported the in silico design and discovery of SRX3254, a highly potent and selective inhibitor of the binding domain 1 (BD1) of the bromodomain protein BRD4 (BRD4-BD1) (Press release, SignalRx, APR 30, 2018, http://www.ireachcontent.com/news-releases/signalrx-announces-discovery-of-potent-and-selective-first-in-class-brd4-bd1-inhibitor-srx3254-681220231.html [SID1234527332]).

SignalRx’s proprietary CRIMP technology platform led to the in silico design and identification of SRX3254. SRX3254 is a novel small-molecule that potently inhibits BRD4-BD1 with a 41-fold selectivity over the closely related binding domain 2 of BRD4 (BRD4-BD2). The inhibition of BRD4-BD1 alone is both necessary and sufficient to achieve anti-cancer activity while the simultaneous inhibition of BRD4-BD2 is associated with some toxicity issues.

"SRX3254 is a very significant breakthrough because most of the known BRD4-BD1 inhibitors don’t have this high degree of selectivity, and their BRD4-BD2 inhibition is a cause of great concern since this is believed to result in unwanted toxicities observed in preclinical and clinical trials. We’re excited about the potential of this low nanomolar to micromolar inhibition difference between BRD4-BD1 and BRD4-BD2" said SignalRx’s scientific advisor and founder Donald L. Durden, MD, PhD.

"With SRX3254, SignalRx is in an excellent position to selectively and potently inhibit BRD4-BD1 with our proprietary compounds and develop pharmaceutical agents that will distinguish themselves from complications derived from inhibiting BRD4-BD2 simultaneously with BRD4-BD1" said Dr. Joseph Garlich, SignalRx’s Chief Scientific Officer. "We rationally design all our anticancer agents and we have now demonstrated both the technology and know-how to make BRD4-BD1 selective inhibitors".

SignalRx is interested in partnering discussions to quickly take these novel small molecules through clinical trials together with companion diagnostics for streamlined development and approval.

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Month: April 2018

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

10-K/A [Amend] – Annual report [Section 13 and 15(d), not S-K Item 405]

SignalRx Announces Discovery of Potent and Selective First-In-Class BRD4-BD1 Inhibitor, SRX3254